Search clinical trials for: Irinotecan liposome

Total 3380 results

Fudan University

Not yet recruiting

Irinotecan Liposome Combined With Anlotinib as Second-line Regimen for SCLC

Small Cell Lung Cancer Recurrent

China
University of Southern California
National Cancer Institute (NCI); Ipsen

Withdrawn

MM-398 and Ramucirumab in Treating Patients With Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

Gastric Adenocarcinoma | Metastatic Gastroesophageal Junction Adenocarcinoma | Unresectable Gastroesophageal Junction Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma | Locally Advanced Unresectable Gastric Adenocarcinoma | Metastatic Unresectable Gastric Adenocarcinoma

United States
Baohui Han

Not yet recruiting

Safety and Efficacy of Adebrelimab Plus Irinotecan Liposome (II) With or Without Famitinib in ES-SCLC Pre-treated With Immunotherapy

Extensive-stage Small-cell Lung Cancer

China
National Cancer Institute (NCI)

Active, not recruiting

Liposomal Irinotecan and Veliparib in Treating Patients With Solid Tumors

Malignant Solid Neoplasm

United States
Emory University
Ipsen; Taiho Oncology, Inc.

Recruiting

TAS102 in Combination With NAL-IRI in Advanced GI Cancers

Gastric Adenocarcinoma | Unresectable Pancreatic Carcinoma | Metastatic Pancreatic Adenocarcinoma | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Colorectal Adenocarcinoma | Stage IV Gastric Cancer | Stage IV Colorectal Cancer | Stage IVA Colorectal Cancer | Stage IVB Colorectal Cancer | Stage... and other conditions

United States
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Study of Irinotecan Hydrochloride Liposome in Advanced Solid Tumors

Advanced Solid Tumors

China
Joel Neal
Nektar Therapeutics

Completed

Phase 2 Etirinotecan Pegol in Refractory Brain Metastases & Advanced Lung Cancer / Metastatic Breast Cancer

Tumors Metastatic to Brain | Stage IV Non-small Cell Lung Cancer (NSCLC) | Recurrent Non-small Cell Lung Cancer (NSCLC) | Extensive-stage Small Cell Lung Cancer (SCLC) | Recurrent Small Cell Lung Cancer (SCLC) | Metastatic Breast Cancer (mBC)

United States
Luye Pharma Group Ltd.

Completed

Irinotecan Hydrochloride Liposome Injection (LY01610) For Advanced Solid Tumors

Advanced Solid Tumor

China
PharmaEngine

Completed

Study of PEP02 as a Second Line Therapy for Metastatic Pancreatic Cancer

Pancreatic Neoplasms

Taiwan, United States
CSPC Ouyi Pharmaceutical Co., Ltd.

Not yet recruiting

Study of Irinotecan Liposome Injection in Patients With Advanced Breast Cance

Advanced Breast Cancer
CSPC Ouyi Pharmaceutical Co., Ltd.

Not yet recruiting

Study of Irinotecan Liposome Injection as Second-line Regimen in Patients With Small Cell Lung Cancer (SCLC)

Small Cell Lung Cancer (SCLC)
Sabine Mueller, MD, PhD
Pacific Pediatric Neuro-Oncology Consortium; The V Foundation for Cancer Research

Completed

CED With Irinotecan Liposome Injection Using Real Time Imaging in Children With Diffuse Intrinsic Pontine Glioma (DIPG) (PNOC 009)

Diffuse Intrinsic Pontine Glioma

United States
Luye Pharma Group Ltd.

Completed

Irinotecan Hydrochloride Liposome Injection (LY01610) For Small Cell Lung Cancer

Small Cell Lung Cancer

China
Luye Pharma Group Ltd.

Recruiting

Study of LY01610 in Patients With Recurrent Small Cell Lung Cancer

Relapsed Small Cell Lung Cancer

China
Yakult Honsha Co., LTD

Completed

Safety Study of IHL-305 (Irinotecan Liposome Injection) to Treat Advanced Solid Tumors

Cancer

United States
Nektar Therapeutics

Completed

NKTR-102 Versus Irinotecan in Patients With Second-Line, Irinotecan-Naïve, KRAS Mutant, Colorectal Cancer

Colorectal Cancer

United States, Belgium, Germany, India, Spain, United Kingdom
Peking Union Medical College Hospital

Not yet recruiting

Treatment of Irinotecan Hydrochloride Liposome Injection II in China: a Real World Study of Pancreatic Cancer Patients (MA-PC-RWS-011)

Pancreatic Cancer

China
Tianjin Medical University Cancer Institute and...
CSPC Ouyi Pharmaceutical Co., Ltd.

Recruiting

Efficacy and Safety of Irinotecan Liposome Injection Combined With 5-FU/LV± Immunotherapy in First-line Gemsitabine + Immunoprogressive Patients With Metastatic Biliary Tract Cancer

Metastatic Biliary Tract Cancer

China
Sun Yat-sen University
CSPC Ouyi Pharmaceutical Co., Ltd.

Not yet recruiting

Doxorubicin Hydrochloride Liposome Combined With Irinotecan Versus VIT Regimen in the Treatment of Pediatric Rhabdomyosarcoma

Rhabdomyosarcoma, Child
Peking University People's Hospital
Peking University Shougang Hospital; Shandong Cancer Hospital and Institute

Recruiting

Weekly Irinotecan Liposomes in Recurrent or Refractory Ewing Sarcoma

Ewing Sarcoma

China
Nelson Yee
Ipsen

Active, not recruiting

Liposomal Irinotecan in Combination With Oxaliplatin, Leucovorin, and 5-fluorouracil for Patients With Locally Advanced Pancreatic Carcinoma:

Locally Advanced Pancreatic Carcinoma(LAPC)

United States
PharmaEngine

Completed

Study of PEP02, Irinotecan or Docetaxel in Gastric or Gastroesophageal Junction Adenocarcinoma

Stomach Neoplasms | Esophageal Neoplasms

Korea, Republic of, Spain, Taiwan, Bosnia and Herzegovina, United Kingdom, Croatia
Roswell Park Cancer Institute
Ipsen

Active, not recruiting

Liposomal Irinotecan, Fluorouracil and Leucovorin in Treating Patients With Refractory Advanced High Grade Neuroendocrine Cancer of Gastrointestinal, Unknown, or Pancreatic Origin

Unresectable Pancreatic Neuroendocrine Carcinoma | Locally Advanced Digestive System Neuroendocrine Carcinoma | Locally Advanced Pancreatic Neuroendocrine Carcinoma | Metastatic Digestive System Neuroendocrine Carcinoma | Metastatic Pancreatic Neuroendocrine Carcinoma | Refractory Digestive... and other conditions

United States
Ipsen

Completed

Study of Irinotecan Liposome Injection (ONIVYDE®) in Patients With Small Cell Lung Cancer (RESILIENT)

Small Cell Lung Cancer

Spain, United States, France, Taiwan, Korea, Republic of, Germany, China, Belgium, Italy, Brazil, Ukraine, Australia, Russian Federation, Serbia, Poland, Hungary, Turkey, Romania
CSPC Ouyi Pharmaceutical Co., Ltd.

Unknown

Bioequivalence Study of Irinotecan Liposome Injection in Chinese Advanced Pancreatic Cancer.

Advanced Pancreatic Cancer

China
Reema A. Patel

Recruiting

GENOCARE: A Prospective, Randomized Clinical Trial of Genotype-Guided Dosing Versus Usual Care

Colorectal Cancer | Pancreatic Cancer

United States
Kuirong Jiang
CSPC Ouyi Pharmaceutical Co., Ltd.

Recruiting

Irinotecan Liposome Combined With Oxaliplatin and Tegafur as Adjuvant Therapy for Pancreatic Cancer

Pancreatic Cancer | Adjuvant Therapy

China
Alchemia Oncology

Unknown

Trial of FOLF(HA)Iri Versus FOLFIRI in mCRC (FOLF(HA)iri)

Metastatic Colorectal Cancer

Australia
Zhejiang Cancer Hospital

Recruiting

Genotype-driven Weekly Irinotecan Liposomes in Combination With Capecitabine-based Neoadjuvant Chemoradiation for Locally Advanced Rectal Cancer

Rectal Cancer

China
Abramson Cancer Center of the University of Pennsylvania

Completed

Etirinotecan Pegol (NKTR-102) in NSCLC

Metastatic Non Small Cell Lung Cancer | Recurrent Non Small Cell Lung Cancer

United States
University of Florida
Ipsen

Active, not recruiting

A Study of the Safety and Activity of Liposomal Irinotecan in Combination With the 5-FU and Oxaliplatin in the Preoperative Treatment of Pancreatic Adenocarcinoma

Pancreatic Adenocarcinoma

United States
Institut de Recherches Internationales Servier

Not yet recruiting

Phase 2 Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Levoleucovorin in Japanese Participants Not Previously Treated for Metastatic Adenocarcinoma of the Pancreas

Metastatic Adenocarcinoma of the Pancreas

Japan
Luye Pharma Group Ltd.

Enrolling by invitation

Safety, Tolerability, Pharmacokinetics (PK), and Primary Clinical Efficacy of LY01616 in Patients With Advanced Solid Tumors

Advanced Solid Tumors

China
Zhejiang University

Not yet recruiting

Irinotecan Liposome for Resectable Pancreatic Cancer With or Without Addebelizumab (CAPT-02)

Resectable Pancreatic Cancer | Neoadjuvant Chemotherapy
Wake Forest University Health Sciences
National Cancer Institute (NCI); Spectrum Pharmaceuticals, Inc

Terminated

Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Recurrent Adult Acute Myeloid Leukemia

United States
Jazz Pharmaceuticals

Completed

Multicenter Study Of CPX-1 (Irinotecan HCl: Floxuridine) Liposome Injection In Patients With Advanced Colorectal Cancer

Colorectal Neoplasms

United States, Canada
National Cancer Institute (NCI)

Completed

Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Breast Carcinoma | Estrogen Receptor Negative | HER2/Neu Negative | Progesterone Receptor Negative | Triple-Negative Breast Carcinoma | Male Breast Carcinoma | Stage IV Breast Cancer AJCC...

United States
University of California, San Francisco

Completed

A Phase I Trial of Nanoliposomal CPT-11 (NL CPT-11) in Patients With Recurrent High-Grade Gliomas

Glioblastoma | Gliosarcoma | Anaplastic Astrocytoma | Anaplastic Oligodendroglioma

United States
National Cancer Institute (NCI)

Completed

Bortezomib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Previously Untreated Symptomatic Multiple Myeloma

DS Stage I Plasma Cell Myeloma | DS Stage II Plasma Cell Myeloma | DS Stage III Plasma Cell Myeloma

United States
Jiangsu HengRui Medicine Co., Ltd.

Unknown

SHR-1316 in Combination With Chemotherapy in Patients With Esophageal Squamous Cell Cancer

Advanced Esophageal Squamous Cell Cancer

China
West China Hospital

Not yet recruiting

Exploratory Study of Irinotecan Liposomes in Maintenance Therapy of Metastatic Colorectal Cancer

Metastatic Colorectal Cancer
Washington University School of Medicine
Merck Sharp & Dohme LLC; Ipsen

Withdrawn

Combination Liposomal Irinotecan and Pembrolizumab For Triple-Negative Breast Cancer (TNBC) With Brain Metastases (BM)

Triple Negative Breast Cancer | Brain Metastases

United States
Hebei Medical University Fourth Hospital

Not yet recruiting

Neoadjuvant Chemoradiation With Nal-IRI and Capecitabine Guided by UGT1A1 Status in Patients With Rectal Cancer

Rectal Cancer
AIO-Studien-gGmbH
Servier Deutschland GmbH; Crolll Gmbh

Active, not recruiting

2nd-line Therapy With Nal-IRI After Gem/Nab-pac in Advanced Pancreatic Cancer - Predictive Role of 1st-line Therapy (PREDICT)

Metastatic Pancreatic Cancer | Locally Advanced Pancreatic Cancer

Germany
West China Hospital

Not yet recruiting

Phase II Study of Irinotecan Liposomes in First-line Treatment of Metastatic Colorectal Cancer

Metastatic Colorectal Cancer
Aurobindo Pharma Ltd
Axis Clinicals Limited

Completed

Steady State Global Bioequivalence Study of Amphotericin B Liposome for Injection 50 mg/ Vial in Fed Condition

Visceral Leishmaniasis

Bangladesh, India
The Affiliated Nanjing Drum Tower Hospital of Nanjing...

Not yet recruiting

Radiotherapy Combined With Irinotecan and Apatinib Followed by PD-1 Antibody and Apatinib for Advanced Solid Tumors

Solid Tumor

China
Ohio State University Comprehensive Cancer Center
National Cancer Institute (NCI)

Recruiting

Vyxeos for Re-induction Treatment of Acute Myeloid Leukemia Patients With Persistent Disease After Induction

Refractory Acute Myeloid Leukemia | Blasts More Than 5 Percent of Bone Marrow Nucleated Cells | Persistent Disease

United States
Hallym University Medical Center
Jeil Pharmaceutical Co., Ltd.

Unknown

Study of Oxaliplatin, Irinotecan, and S-1 in Biliary Tract Cancer

Biliary Tract Neoplasm

Korea, Republic of
Shanghai Zhongshan Hospital
CSPC Ouyi Pharmaceutical Co., Ltd.

Recruiting

Dose Escalation and Expansion Clinical Trial of Irinotecan Liposome Combined With Oxaliplatin and 5-FU/LV Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

China

Search clinical trials for: Irinotecan liposome

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bangladesh

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations